000168193 001__ 168193
000168193 005__ 20240229133600.0
000168193 0247_ $$2doi$$a10.1093/carcin/bgab026
000168193 0247_ $$2pmid$$apmid:33780524
000168193 0247_ $$2ISSN$$a0143-3334
000168193 0247_ $$2ISSN$$a1460-2180
000168193 0247_ $$2altmetric$$aaltmetric:102978172
000168193 037__ $$aDKFZ-2021-00733
000168193 041__ $$aEnglish
000168193 082__ $$a610
000168193 1001_ $$aAglago, Elom K$$b0
000168193 245__ $$aPlasma concentrations of advanced glycation end-products and colorectal cancer risk in the EPIC study.
000168193 260__ $$aOxford$$bOxford Univ. Press$$c2021
000168193 3367_ $$2DRIVER$$aarticle
000168193 3367_ $$2DataCite$$aOutput Types/Journal article
000168193 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1626273545_24480
000168193 3367_ $$2BibTeX$$aARTICLE
000168193 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000168193 3367_ $$00$$2EndNote$$aJournal Article
000168193 500__ $$a2021 May 28;42(5):705-713
000168193 520__ $$aAdvanced glycation end-products (AGEs) are a heterogeneous group of compounds formed by the non-enzymatic reaction between amino-acids and reducing sugars, or dicarbonyls as intermediate compounds. Experimental studies suggest that AGEs may promote colorectal cancer, but prospective epidemiologic studies are inconclusive. We conducted a case-control study nested within a large European cohort. Plasma concentrations of three protein-bound AGEs: N ε-(carboxy-methyl)lysine (CML), N ε-(carboxy-ethyl)lysine (CEL) and N δ-(5-hydro-5-methyl-4-imidazolon-2-yl)-ornithine (MG-H1) were measured by ultra-performance liquid chromatography tandem mass-spectrometry in baseline samples collected from 1,378 incident primary colorectal cancer cases and 1,378 matched controls. Multivariable-adjusted odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression for colorectal cancer risk associated with CML, CEL, MG-H1, total AGEs, and [CEL+MG-H1: CML] and [CEL:MG-H1] ratios. Inverse colorectal cancer risk associations were observed for CML (OR comparing highest to lowest quintile, ORQ5vs.Q1=0.40, 95%CI:0.27-0.59), MG-H1 (ORQ5vs.Q1=0.73, 95%CI:0.53 - 1.00) and total AGEs (OR Q5vs.Q1=0.52, 95%CI:0.37 - 0.73) whereas no association was observed for CEL. A higher [CEL+MG-H1: CML] ratio was associated with colorectal cancer risk (ORQ5vs.Q1=1.91, 95%CI:1.31-2.79). The associations observed did not differ by sex, or by tumour anatomical subsite. Although individual AGEs concentrations appear to be inversely associated with colorectal cancer risk, a higher ratio of methylglyoxal-derived AGEs versus those derived from glyoxal (calculated by [CEL+MG-H1: CML] ratio) showed a strong positive risk association. Further insight on the metabolism of AGEs and their dicarbonyls precursors, and their roles in colorectal cancer development is needed.
000168193 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000168193 588__ $$aDataset connected to CrossRef, PubMed,
000168193 650_7 $$2Other$$aAdvanced glycation end-product
000168193 650_7 $$2Other$$acolorectal cancer
000168193 650_7 $$2Other$$aglycotoxin
000168193 7001_ $$aSchalkwijk, Casper G$$b1
000168193 7001_ $$aFreisling, Heinz$$b2
000168193 7001_ $$aFedirko, Veronika$$b3
000168193 7001_ $$aHughes, David J$$b4
000168193 7001_ $$aJiao, Li$$b5
000168193 7001_ $$aDahm, Christina C$$b6
000168193 7001_ $$aOlsen, Anja$$b7
000168193 7001_ $$aTjønneland, Anne$$b8
000168193 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b9$$udkfz
000168193 7001_ $$0P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aJohnson, Theron$$b10$$udkfz
000168193 7001_ $$aSchulze, Matthias B$$b11
000168193 7001_ $$aAleksandrova, Krasimira$$b12
000168193 7001_ $$aMasala, Giovanna$$b13
000168193 7001_ $$aSieri, Sabina$$b14
000168193 7001_ $$aSimeon, Vittorio$$b15
000168193 7001_ $$aTumino, Rosario$$b16
000168193 7001_ $$aMacciotta, Alessandra$$b17
000168193 7001_ $$aBueno-de-Mesquita, Bas$$b18
000168193 7001_ $$aSkeie, Guri$$b19
000168193 7001_ $$aGram, Inger Torhild$$b20
000168193 7001_ $$aSandanger, Torkjel$$b21
000168193 7001_ $$aJakszyn, Paula$$b22
000168193 7001_ $$aSánchez, Maria-Jose$$b23
000168193 7001_ $$aAmiano, Pilar$$b24
000168193 7001_ $$aColorado-Yohar, Sandra M$$b25
000168193 7001_ $$aGurrea, Aurelio Barricarte$$b26
000168193 7001_ $$aPerez-Cornago, Aurora$$b27
000168193 7001_ $$aMayén, Ana-Lucia$$b28
000168193 7001_ $$aWeiderpass, Elisabete$$b29
000168193 7001_ $$aGunter, Marc J$$b30
000168193 7001_ $$aHeath, Alicia K$$b31
000168193 7001_ $$aJenab, Mazda$$b32
000168193 773__ $$0PERI:(DE-600)1474206-8$$a10.1093/carcin/bgab026$$gp. bgab026$$n5$$p705-713$$tCarcinogenesis$$v42$$x1460-2180$$y2021
000168193 909CO $$ooai:inrepo02.dkfz.de:168193$$pVDB
000168193 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000168193 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)79ab945544e5bc017a2317b6146ed3aa$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000168193 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000168193 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000168193 9141_ $$y2021
000168193 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2021-02-04$$wger
000168193 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCARCINOGENESIS : 2019$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-02-04
000168193 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2021-02-04
000168193 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000168193 980__ $$ajournal
000168193 980__ $$aVDB
000168193 980__ $$aI:(DE-He78)C020-20160331
000168193 980__ $$aUNRESTRICTED